PMID- 35535438
OWN - NLM
STAT- MEDLINE
DCOM- 20221123
LR  - 20221217
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 11
IP  - 22
DP  - 2022 Nov
TI  - Establishment of an age- and tumor microenvironment-related gene signature for 
      survival prediction in prostate cancer.
PG  - 4374-4388
LID - 10.1002/cam4.4776 [doi]
AB  - BACKGROUND: The incidence of prostate cancer (PCa) increases with age, and age 
      and tumor microenvironment (TME) have important roles in the development of PCa, 
      while the underlying mechanisms have not been fully elucidated. MATERIALS AND 
      METHOD: The Cancer Genome Atlas-Prostate Adenocarcinoma (TCGA-PRAD) RNA-Seq, the 
      Surveillance, Epidemiology, and End Results (SEER-PRAD), and ESTIMATE data were 
      downloaded, and the clinical information of PRAD patients in our cohort was 
      collected. The associations among age, TME, and PCa were analyzed. The age- and 
      TME-related risk score (ATRS) of each TCGA-PRAD sample was calculated based on 
      the identified age- and TME-related differentially expressed genes (DEGs), and 
      the correlation of ATRS with immune-related characteristics of PCa patients was 
      analyzed, and the ATRS-based overall survival (OS)-predicting nomogram was also 
      established. RESULTS: Age was correlated with OS, PSA level, tumor stage, T 
      stage, N stage, Gleason score, nerve invasion of PCa, and age was positively 
      correlated with stromal, immune, and ESTIMATE scores. The compositions of immune 
      cells of TCGA-PRAD patients altered with age. Nine age- and TME-related 
      prognostic DEGs were identified, and the ATRS of each TCGA-PRAD patient was 
      calculated based on the identified nine DEGs. The ATRS was associated with the 
      expression of immune checkpoints and intratumoral cytolytic activity, and the 
      ATRS-based nomogram performed well in predicting the outcomes of PCa patients. 
      CONCLUSIONS: Age and TME had crucial roles in PCa, and the ATRS gene signature 
      was associated with the immune-related characteristics of PCa patients, which 
      showed good performance in predicting OS of PCa patients.
CI  - (c) 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Chen, Lei
AU  - Chen L
AUID- ORCID: 0000-0001-6893-2603
AD  - Department of Urology, The First Affiliated Hospital of Anhui Medical University, 
      Hefei, China.
AD  - Institute of Urology, Anhui Medical University, Hefei, China.
AD  - Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical 
      University, Hefei, China.
FAU - Zhang, Meng
AU  - Zhang M
AUID- ORCID: 0000-0003-4935-4005
AD  - Department of Urology, The First Affiliated Hospital of Anhui Medical University, 
      Hefei, China.
AD  - Institute of Urology, Anhui Medical University, Hefei, China.
AD  - Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical 
      University, Hefei, China.
FAU - Zhou, Jun
AU  - Zhou J
AD  - Department of Urology, The First Affiliated Hospital of Anhui Medical University, 
      Hefei, China.
AD  - Institute of Urology, Anhui Medical University, Hefei, China.
AD  - Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical 
      University, Hefei, China.
FAU - Zhang, Li
AU  - Zhang L
AD  - Department of Urology, The First Affiliated Hospital of Anhui Medical University, 
      Hefei, China.
AD  - Institute of Urology, Anhui Medical University, Hefei, China.
AD  - Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical 
      University, Hefei, China.
FAU - Liang, Chaozhao
AU  - Liang C
AUID- ORCID: 0000-0003-2317-1323
AD  - Department of Urology, The First Affiliated Hospital of Anhui Medical University, 
      Hefei, China.
AD  - Institute of Urology, Anhui Medical University, Hefei, China.
AD  - Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical 
      University, Hefei, China.
AD  - Anhui Institute of Translational Medicine, Hefei, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220509
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Male
MH  - Humans
MH  - *Tumor Microenvironment/genetics
MH  - Biomarkers, Tumor/genetics
MH  - Gene Expression Regulation, Neoplastic
MH  - *Prostatic Neoplasms/pathology
MH  - Prognosis
PMC - PMC9678094
OTO - NOTNLM
OT  - age
OT  - gene signature
OT  - nomogram
OT  - prostate cancer
OT  - tumor microenvironment
COIS- The authors declare that there is no conflict of interest regarding the 
      publication of this paper.
EDAT- 2022/05/11 06:00
MHDA- 2022/11/24 06:00
PMCR- 2022/05/09
CRDT- 2022/05/10 03:03
PHST- 2022/04/20 00:00 [revised]
PHST- 2022/02/12 00:00 [received]
PHST- 2022/04/10 00:00 [accepted]
PHST- 2022/05/11 06:00 [pubmed]
PHST- 2022/11/24 06:00 [medline]
PHST- 2022/05/10 03:03 [entrez]
PHST- 2022/05/09 00:00 [pmc-release]
AID - CAM44776 [pii]
AID - 10.1002/cam4.4776 [doi]
PST - ppublish
SO  - Cancer Med. 2022 Nov;11(22):4374-4388. doi: 10.1002/cam4.4776. Epub 2022 May 9.